AJP - Endo Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Endocrinol Metab 295: E842-E850, 2008. First published July 29, 2008; doi:10.1152/ajpendo.90359.2008
0193-1849/08 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
295/4/E842    most recent
90359.2008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Phillips, S. A.
Right arrow Articles by Henry, R. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Phillips, S. A.
Right arrow Articles by Henry, R. R.

Adiponectin secretion and response to pioglitazone is depot dependent in cultured human adipose tissue

Susan A. Phillips,1,2 Theodore P. Ciaraldi,1,3 Deborah. K. Oh,1,3 Michelle K. Savu,1,4 and Robert R. Henry1,3

1Veterans Affairs San Diego Healthcare System, La Jolla; and Departments of 2Pediatrics, 3Medicine, and 4Surgery, University of California, San Diego, California

Submitted 11 April 2008 ; accepted in final form 23 July 2008


   ABSTRACT
TOP
 ABSTRACT
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 DISCLOSURES
 REFERENCES
 
The subcutaneous (S) and visceral (V) adipose tissue (AT) depots are increasingly recognized as distinct. To test the hypothesis that depot differences exist for adiponectin, fresh and cultured human VAT and SAT from obese type 2 diabetic (T2D) and obese nondiabetic (ND) subjects was examined to determine whether differences in adiponectin content and secretion occurred as a function of depot studied, diabetic status, and response to thiazolidinedione treatment. VAT and SAT were obtained by biopsy and AT explants cultured in defined media for 7 days. Protein expression was assessed by Western blot. Adiponectin content of conditioned medium was determined by radioimmunoassay. Diabetic status had no effect on adiponectin secretion over days 0–2 of culture. In ND SAT, secretion fell over days 2–4 but was sustained at greater levels vs. T2D SAT. In both ND and T2D VAT, adiponectin secretion was low, similar to T2D SAT. Over the 7-day culture period, cellular adiponectin increased in ND SAT and VAT; it remained unchanged in T2D SAT and VAT. Pioglitazone increased adiponectin secretion and content in all SAT. Pioglitazone failed to increase adiponectin secretion from either ND or T2D VAT and increased cellular content only in ND VAT. AT depot differences exist in the secretion of adiponectin and responsiveness to thiazolidinedione treatment. These data suggest that SAT, not VAT, appears to be the major contributor to increased circulating adipopnectin levels in response to pioglitazone treatment.

adipose tissue physiology; type 2 diabetes mellitus; body fat distribution; thiazolidinediones; leptin

ADIPOSE TISSUE (AT) is recognized to play an important role in the regulation of lipid/carbohydrate metabolism, energy homeostasis, and insulin sensitivity (55) via release of metabolically active products that regulate insulin sensitivity and fat metabolism (27). Many AT products exert opposing actions on insulin sensitivity, inflammation, and fatty acid metabolism. For example, AT products IL-6, TNF-{alpha}, and resistin may impair insulin sensitivity, increase circulating free fatty acids, and exert proinflammatory effects, whereas others such as adiponectin exert insulin-sensitizing effects, reduce free fatty acids, and dampen inflammation (28). The metabolic impact of a given AT depot is therefore related to the relative profile or balance of mediator release.

AT is distributed to a variety of locations, and in humans contributions of SAT and VAT can be distinguished (reviewed in Ref. 59). Individuals with increased visceral (V)AT are at higher risk of developing the metabolic syndrome, type 2 diabetes (T2D), and cardiovascular disease (32, 59) than those with similar amounts of AT as subcutaneous (S)AT (34). Underlying these findings are depot differences in gene and protein expression (36, 37). These findings lend support to the idea that different AT depots are functionally distinct metabolic units.

Circulating levels of adiponectin are low in obese and insulin-resistant subjects (62) and are predictive for development of T2D (30). In contrast, adiponectin is high in lean and insulin-sensitive subjects (50). Interestingly, serum adiponectin levels are inversely correlated with waist circumference and intra-abdominal fat accumulation (48), suggesting that depot differences likely exist in adiponectin secretion. Depot differences in adiponectin gene expression have been reported by some (23, 46, 49) but not all investigators (18, 53, 63) and importantly are not always correlated with AT secretion (49) or circulating levels (30). Little is known regarding posttranscriptional regulation of adiponectin. However, thialzolidinediones (TZDs), potent insulin sensitizers, are recognized to augment cellular adiponectin and its circulating levels two- to threefold (13).

To determine whether reported in vivo correlations between AT depot distribution and circulating adiponectin reflect underlying tissue differences in adiponectin content and secretion, we examined adiponectin content and secretion in human SAT and VAT explants. Given the low circulating levels of adiponectin associated with T2D and the increases associated with TZD treatment, we asked whether these differences might also reflect differences in depot responsiveness.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 DISCLOSURES
 REFERENCES
 
Human subjects. A total of 50 obese subjects were recruited for this study. The Institutional Review Board at the University of California San Diego approved this research, and all subjects gave informed consent. Of the 50 subjects, 26 were diabetic. The determination of diabetic status was made on the basis of a fasting blood glucose >125 or a 2-h glucose >200 mg/dl following a 75-g oral glucose load [oral glucose tolerance test (OGTT)] (8). Characteristics of study subjects are shown in Table 1. Fasting serum lipids and glucose were determined using standard clinical assays. Waist circumference was measured as the abdominal circumference at the level of the iliac crest.


View this table:
[in this window]
[in a new window]

  		Table 1. Clinical characteristics of subjects

 
Adipose tissue biopsy. Human AT was obtained from a total 26 subjects [13 T2D and 13 nondiabetic (ND)] undergoing laparoscopic gastric bypass with Roux-en-Y gastroenteroscopic surgery for the treatment of morbid obesity following an overnight fast. Diabetic subjects continued treatment with either metformin alone, metformin plus a sulfonylurea, or insulin; subjects on a TZD were excluded. Abdominal SAT was obtained from the lower abdominal region outside the fascia superficialis, and VAT was obtained from the greater omentum. In 13 (8 T2D AND 5 ND) subjects, paired samples of SAT and VAT were obtained. SAT was also obtained from 24 obese subjects (13 T2D and 11 ND) by needle biopsy as previously described (11).

Adipose explant culture. All procedures for AT explant culture were carried out using sterile technique. Following biopsy or surgery, AT was placed into sterile filtered HEPES-salts (HS) buffer containing (in mmol/l) 150 NaCl, 5 KC1, 1.2 MgSO4, 1.2 CaC12, 2.5 NaH2PO4, 10 HEPES, and 2 pyruvate, pH 7.4, and supplemented with 4% BSA (Roche Diagnostic, Indianapolis, IN) washing buffer (WB) and immediately transported under aseptic conditions to the laboratory. AT was washed free of lipid and blood clots with WB and then processed further by cutting into 5- to 10-mg pieces, washed, and placed in WB for 30-min recovery. AT was then weighed and divided for explant culture and studies on freshly isolated adipocytes. AT explants were cultured (1 g AT/30 ml) under an atmosphere of 5% CO2 in air at 37°C in defined medium (DM) (1:1 DME low/Ham's F-10 containing 5 mM glucose supplemented with 25 mM HEPES, 15 mM NaHCO3, 2 mM glutamine and 100 U/ml pencillin, 0.1 mg/ml streptomycin, plus 1 nM insulin, 30 nM dexamethasone, 3.3 µM D-biotin, 1.7 µM D-pantothenic acid, and 10 µg/ml holotransferrin) for culture, which is a modification of Refs. 58 and 2. Pioglitazone (Pio) was added as indicated (Takeda, Osaka, Japan) to achieve a final concentration of 10 µM, equivalent to 3.92 µg/ml, a concentration in the range of serum levels of Pio-treated T2D subjects (7). Samples of the conditioned medium (CM) were taken every 24 h, and medium was changed every 2 days. Cell viability was assessed by multiple measurements. Media glucose and lactate release as determined by dual analyzer (YSI, Yellow Springs, OH), pH, fat cell size, and histology did not significantly change over the culture period, regardless of depot source or diabetic status, nor did acute insulin stimulation of glucose transport differ significantly between adipocytes isolated from fresh or cultured AT. Lactate dehydrogenase (LDH) content of CM was assessed as an indicator of cell lysis at baseline, day 2, day 4, and day 6; no significant increase in LDH occurred over the culture period. Protein expression of peroxisome proliferator-activated receptor-{gamma} (PPAR{gamma}) remained stable over time in culture. Aliquots of CM were stored at –70°C for later analysis.

Isolation, protein extraction, and expression of adipocyte proteins. For all assays, adipocytes were isolated, as previously described (11), from either fresh AT or from twice-WB-washed AT explants following their culture. Isolated adipocytes were then concentrated by centrifugation (50 g), rapidly washed twice at 17°C in insulin-free, BSA-free HWS buffer, and proteins were extracted as previously described (54). Electrophoresis, transfer, and Western blotting of proteins were preformed according to standard methods, using primary monoclonal anti-human adiponectin (BD Bioscience, San Diego, CA) polyclonal anti-human PPAR{gamma}1–2 (BIOMOL, Plymouth Meeting, PA), and secondary horseradish peroxidase-conjugated anti-mouse and anti-rabbit IgG (Amersham, Arlington Heights, IL). For antibody detection SuperSignal (Pierce, Rockford, IL) enhanced chemiluminesence substrate was used, followed by densitometry and quantitation using ScanAnalysis software (Biosoft, Cambridge, UK). An internal standard was included in each gel to permit for correction of variability between blots.

Glucose transport (9) into adipocytes and adipocyte sizing (10) were performed as described previously.

Measurement of cytokines. Adiponectin and leptin content of CM and serum adiponectin were measured using radioimmunoassay kits (Linco, St. Louis, MO) and Bio-Rad's Bio-Plex human cytokine assay (Hercules, CA). All samples were assayed in duplicate. The lower limit of detection with the adiponectin assay was 3 µg/ml; the inter- and intra-assay coefficients of variation were 7 and 11%, respectively. For the leptin assay, the corresponding values were 0.5 ng/ml and 5 and 5%. Screening of cytokine content of the CM was preformed by hybridizing the medium with antibody-coated membranes according to manufacturer's instructions (RayBiotech, San Diego, CA). Media IL-6, IL-8, IL-1β, TNF-{alpha}, monocyte chemoattractant protein-1 (MCP-1), and IL-10 were additionally quantified by ELISA (R&D Systems, Minneapolis, MN).

Statistical analysis. Results are presented as means ± SE for the indicated numbers of patients. Due to limitations in sample availability, not all analyses were performed in every subject. The number of subjects studied is given in the legend of each figure. Clinical characteristics of the subsets of subjects studied in the different experiments did not differ from the average of the total group. Statistical analysis was performed using the GraphPad Prism program v.4 (Intuitive Software, San Diego, CA). Statistical significance was evaluated with Student's t-test for unpaired or paired data when appropriate and repeated-measures ANOVA. Significance was accepted at the P < 0.05 level.


   RESULTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 DISCLOSURES
 REFERENCES
 
Serum adiponectin levels in obese diabetic and obese ND subjects. To focus on the impact of T2D on adiponectin secretion, we recruited subjects who were matched for BMI, weight, waist circumference, and lipid levels. Only fasting glucose and Hb A1c levels differed between the subject groups (Table 1). There was a tendency (P = 0.16) for T2D subjects to have lower serum adiponectin levels (8.6 ± 1.4 vs. 10.9 ± 1.8 µg/ml). Serum adiponectin levels of a subset (n = 23) of subjects were correlated with glucose disposal rate (GDR) as determined from hyperinsulinemic euglycemic clamp (17) (r = 0.49, P = 0.01) a measure of whole body insulin action, although no correlation was found between BMI and serum adiponectin levels (data not shown).

Impact of depot and diabetic status on adiponectin secretion. Human SAT and VAT explants were cultured in defined medium for 1 wk. Over the first 2 days (days 0–2) of culture, no depot or diabetes-related differences were evident in the rate of adiponectin secretion by AT (Fig. 1, A and B). GDR was positively correlated with both serum adiponectin (r = 0.49, P = 0.01) and SAT days 0–2 adiponectin secretion (r = 0.56, P = 0.01), suggesting that days 0–2 culture is reflective of the in vivo environment including the impact of antidiabetic medication. By day 4 of culture, both SAT and VAT secreted less adiponectin. ND SAT (Fig. 1A), however, showed a greater tendency for adiponectin secretion compared with VAT (Fig. 1A) (554 ± 151 and 349 ± 164 µg/g), becoming statistically significant by day 6 (583 ± 108 and 126 ± 25 µg/g, P = 0.04). Adiponectin secretion by T2D SAT and VAT (Fig. 1B) was comparable over days 0–2 (1,036 ± 245 and 1,159 ± 316, SAT and VAT, respectively), decreased in parallel by day 4 (287 ± 97 vs. 310 ± 97), and remained low at day 6 (217 ± 60 vs. 234 ± 68, SAT and VAT, respectively). Interestingly, the pattern of reduced adiponectin secretion seen in T2D SAT (Fig. 1B) was reminiscent of that exhibited by ND VAT (Fig. 1A).


Figure 1
View larger version (13K):
[in this window]
[in a new window]

  		Fig. 1. Adiponectin secretion by nondiabetic (ND; A) and type 2 diabetic (T2D; B) adipose tissue (AT) explants. Explants were cultured for 7 days in F-10 defined medium (DM) containing 30 nM Dex and 1 nM insulin. Medium was sampled every 48 h and analyzed by RIA for adiponectin (Ad) content. Results are reported as average ± SE; n = 10 for ND subcutaneous (S)AT and n = 8 for ND visceral (V)AT; n = 13 for T2D SAT and n = 8 for T2D VAT. Open bars, SAT; filled bars, VAT. *P < 0.05 vs. secretion on day 2.

 
Adiponectin secretion by SAT on days 0–2 and between days 0–2 and days 2–4 did not differ according to diabetic status (Fig. 1, A and B). However, between days 2–4 and days 4–6, diabetic status impacted secretion, with greater rates of adiponectin secretion from ND SAT vs. T2D SAT. By days 4–6, ND SAT secreted approximately twofold more adiponectin than T2D SAT (Fig. 1, A vs. B). In contrast, no diabetes-related difference was observed in VAT. These data suggest that SAT may possess greater potential for adiponectin secretion than VAT and that this depot difference is lost with DM. In the subset of subjects where there was paired VAT and SAT, the results were similar to the pooled data.

Although a number of adipocyte properties and functions are stable under the defined conditions of the explant culture, the observed decline in adiponectin secretion could be indicative of a potential artifact of the culture system. To address this concern, we assessed the secretion from AT of another key adipokine, leptin. In contrast to adiponectin, leptin secretion from ND SAT and VAT and from T2D SAT and VAT was sustained throughout the culture period (see Fig. 5), suggesting that the change in adiponectin secretion is a specific response. No diabetic impact was observed on the capacity of AT to maintain leptin secretion.


Figure 5
View larger version (13K):
[in this window]
[in a new window]

  		Fig. 5. Leptin secretion by cultured SAT and VAT explants: effect of PPAR{gamma} agonist Pio treatment. Leptin secretion by SAT (A) and VAT (B) from combined ND and T2D AT explants. Explants were cultured for 7 days in DM containing 30 nM Dex and 1 nM insulin ± 10 µM Pio. Medium was sampled every 2 days and analyzed by RIA for leptin content. Results are reported as average ± SE. SAT: n = 16 –Pio and n = 8 +Pio; VAT: n = 14 –Pio and n = 10 +Pio. VAT. Open bars, control; hatched bars, +Pio. *P < 0.05 vs. secretion on day 2; {dagger}P < 0.05 vs. paired control.

 
Impact of depot and diabetic status on cellular adiponectin content. Protein expression of adiponectin was compared in adipocytes isolated from fresh and 1-wk-cultured AT explants (Fig. 2). Adiponectin was detected by Western blot as a single band migrating at ~30 kDa. No correlation was found between serum adiponectin and adiponectin protein content in adipocytes isolated from fresh or explant cultures of VAT and/or SAT adipocytes (data not shown). No depot or diabetic differences were detected in adiponectin content of freshly isolated fat cells. However, and in contrast to the observed decreases in adiponectin secretion during culture, adiponectin content increased in cultured ND AT, regardless of depot. Adiponectin content remained unchanged in T2D AT over the culture period (Fig. 2). These results show that depot-dependent and diabetic-associated differences in adiponectin secretion seen with time in culture are not mirrored, or accounted for, by changes in cell content.


Figure 2
View larger version (20K):
[in this window]
[in a new window]

  		Fig. 2. Cell content of adiponectin in adipocytes from freshly isolated and cultured AT. Adipocyte protein extracts were prepared from fresh (F) and 7-day-cultured (Cx) ND and T2D AT and analyzed by immunoblotting with anti-adiponectin antibody as described in MATERIALS AND METHODS. Top: representative autoradiographs. Bottom: quantitation of autoradiographs. Adiponectin expression is presented as a percentage of the value determined from analysis of fresh cells from the same individual, average ± SE; n = 9 for ND and n = 7 for T2D SAT; n = 12 for ND and n = 8 for T2D VAT. Open bars, ND; hatched bars, T2D. *P < 0.05 vs. value in freshly isolated adipocytes.

 
TZD regulation of adiponectin content and secretion. TZDs are selective PPAR{gamma} agonists that serve as potent insulin sensitizers. In vivo, administration of TZDs to diabetic subjects results in a two- to threefold increase in circulating adiponectin (40). To determine direct and depot-specific effects of TZD treatment on adiponectin secretion, ND and T2D SAT and VAT were cultured in the absence or presence of 10 µM Pio. In ND SAT, Pio treatment resulted in a two- to threefold increase in adiponectin secretion by days 2–4 that was sustained through days 4–6 of culture, restoring adiponectin secretion by SAT to levels observed at days 0–2 (Fig. 3A). No Pio response was detected in ND VAT (Fig. 3B). Depot differences were also observed in T2D AT. Pio addition to T2D SAT resulted in a partial rescue of adiponectin secretion (Fig. 4A), increasing secretion 1.8-fold by days 2–4 and over twofold by days 4–6 of culture, although not to the levels seen in ND SAT (Fig. 3A), suggesting an impact of diabetic status on SAT responsiveness to Pio in its capacity for adiponectin secretion. Again, no response was detected in VAT; levels remained low throughout the culture period (Fig. 4B). These results suggest a difference in the relative responsiveness of the SAT vs. the VAT depot to TZD effects on adiponectin secretion.


Figure 3
View larger version (14K):
[in this window]
[in a new window]

  		Fig. 3. Adiponectin secretion by cultured ND SAT (A) and VAT (B) explants: effect of PPAR{gamma} agonist pioglitazone (Pio) treatment. Explants were cultured for 7 days in DM ± Pio (10 µM). Medium was sampled every 2 days and analyzed by RIA for adiponectin content. Results are reported as average ± SE; n = 12 for SAT and n = 9 for VAT. open bars, control; hatched bars, +Pio. *P < 0.05 vs. secretion on day 2; {dagger}P < 0.05 vs. paired control.

 

Figure 4
View larger version (13K):
[in this window]
[in a new window]

  		Fig. 4. Adiponectin secretion by cultured T2D SAT (A) and VAT (B) explants: effect of PPAR{gamma} agonist Pio treatment. Explants were cultured for 7 days in DM ± Pio (10 µM). Medium was sampled every 2 days and analyzed by RIA for adiponectin content. Results are reported as average ± SE; n = 13 for SAT and n = 10 for VAT. Open bars, control; hatched bars, +Pio. *P < 0.05 vs. secretion on day 2; {dagger}P < 0.05 vs. paired control.

 
Pio treatment significantly increased cellular adiponectin in adipocytes isolated from 7-day-cultured ND and T2D SAT explants (Table 2), mirroring the treatment associated increases in SAT adiponectin secretion (Figs. 3A and 4A). Interestingly, ND but not T2D VAT (Table 2) also responded to Pio treatment with an increase in cellular adiponectin, although the increase in ND VAT occurred without a parallel increase in adiponectin secretion (Fig. 3B). Thus, regardless of diabetic status, SAT retained the capacity to respond to Pio with an upregulation of cellular adiponectin, whereas in VAT diabetic status impacted Pio responsiveness (Table 2). These differences in AT depot behavior and TZD responsiveness may underlie observed differences in adiponectin levels and TZD responsiveness in both ND and T2D subjects. The failure of VAT to increase secreted and cellular adiponectin in response to Pio treatment was not due to a deficiency in PPAR{gamma} protein expression. Indeed, PPAR{gamma} expression in VAT was comparable to that in SAT for both T2D (0.63 ± 0.22 vs. 0.62 ± 0.10 AU/µg protein, VAT vs. SAT, respectively; n = 4) and ND (0.73 ± 0.17 vs. 0.78 ± 0.35 AU/µg protein; n = 11).


View this table:
[in this window]
[in a new window]

  		Table 2. Cellular adiponectin and response to pioglitazone

 
The above findings suggest a greater relative influence of AT depot differences compared with diabetic status in predicting changes in adiponectin. One potential mechanism for the observed depot differences in adiponectin responsiveness could be a change in the secretion of inflammatory cytokines. To evaluate for this possibility, CM from cultured SAT and VAT explants was screened for inflammatory cytokine content using a commercial protein microarray; no differences between depots were detected. To quantitatively determine whether changes occurred in cytokines previously identified as products of AT, IL-8, IL-10, IL-6, MCP-1, TNF-{alpha}, and leptin content of the conditioned medium, over time in culture, were determined by ELISA or Bio-Plex. All cytokines except leptin decreased in parallel with adiponectin (Table 3). Leptin secretion, in contrast to adiponectin, increased at days 2–4 in SAT (Fig. 5A) but not in VAT (Fig. 5B). Interestingly, TZDs act to reduce leptin expression in adipocytes (16). Consistent with this reported activity of PPAR{gamma} agonists on leptin gene regulation, Pio treatment of SAT and VAT explants significantly reduced the secretion of leptin into the medium (Fig. 5, A and B). Moreover, this response was earlier and of a greater magnitude in VAT, suggesting a greater sensitivity of the VAT depot to this TZD effect, in contrast to its failure to respond to TZD augmentation of adiponectin secretion (Figs. 3B and 4B).


View this table:
[in this window]
[in a new window]

  		Table 3. Changes in cytokine secretion over days 2–4 of culture: depot effect

 

   DISCUSSION
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
DISCLOSURES
 REFERENCES
 
Adipose tissue is a dynamic tissue whose function impacts a number of key physiological processes, including inflammation, reproduction, energy homeostasis, and lipid and glucose metabolism. Complicating this evolving and important role of AT in whole body physiology is the observation that AT is not homogeneous in function.

AT is distributed to a number of distinct regional depots. The literature suggests that this pattern of distribution, particularly in regard to the relative proportion of VAT and SAT, may be an important indicator of metabolic abnormalities (35). The size of the VAT depot has been positively correlated with insulin resistance and cardiovascular risk (19) and is a better determinant of insulin sensitivity than SAT (12). Direct evidence for regional differences in AT behavior comes from studies of preadipocytes, adipocytes, and cultured tissue explants that extend to adipocyte gene (44) and protein expression (44, 59) as well as to functional measures (5, 20). Depot differences also exist at the level of secretion (reviewed in Ref. 59). A high degree of correlation exists between VAT mass and circulating levels of proinflammatory cytokines (31, 41, 42). At the tissue level, depot differences have been documented in the secretion of a number of inflammatory cytokines, including, leptin (56), plasminogen activator inhibitor-1 (PAI-1) (1), IL-6 (24), and MCP-1 (6).

Adiponectin is a novel adipocyte-specific protein possessing important insulin-sensitizing, antiatherogenic (64), and anti-inflammatory properties (47). Circulating levels of adiponectin are positively correlated with insulin sensitivity (27, 54), and decreases in adiponectin parallel the development of insulin resistance (30). Unlike other adipokines, such as TNF-{alpha}, resistin, leptin, and IL-6, adiponectin circulates in inverse proportion to fat mass (3). However, the regional distribution of AT between the SAT and the intra-abdominal or VAT depot may be a more important factor. In visceral adipocytes, reductions in circulating levels of adiponectin have been associated with both reduced (23, 39) and unchanged (18, 49, 63) levels of gene expression. Moreover, changes in adiponectin secretion may occur in the absence of parallel changes in gene expression (30, 49), suggesting that circulating adiponectin may be regulated at the posttranslational and/or secretory level.

To better understand the impact of regional fat distribution on adiponectin production, we compared adiponectin secretion from freshly obtained and cultured SAT and VAT explants of individual obese subjects. Our findings of no depot or diabetic differences in adiponectin secretion over days 0–2 (Fig. 1, A and B) are consistent with previous reports on cultured adipocytes from ND subjects incubated for 12–24 h (18, 45) and for 48 h (22).

To investigate properties intrinsic to AT, independent from the in vivo environment, we proceeded to study AT depot behavior over time in culture. In ND AT, adiponectin secretion from SAT was sustained in culture, whereas that from VAT fell (Fig. 1A). In contrast, in T2D AT, neither SAT nor VAT was capable of sustained adiponectin secretion over the culture period, a finding mirroring in vivo observations of lower circulating levels of adiponectin in T2D vs. ND subjects matched for BMI (29). Our results in ND AT differ from those of Perrini et al. (49), who report greater adiponectin release by visceral adipocytes at 48 h. Important methodological differences, however, exist between our studies. First, and most importantly, our studies reflect results from explant compared with isolated adipocyte culture. Although each method has advantages, we chose explant culture for its proven utility in the analysis of long-term regulation of adipocyte function in vitro (25). Explant culture uniquely preserves both the extracellular matrix, providing structural support for adipocytes, and the paracrine influence of the many constitutent cell types of AT that influence adipocyte function. Second, our studies reflect AT behavior over a 7-day compared with a 48-h period, permitting AT function to be studied in isolation from the influence of in vivo metabolism and hormonal influences.

Circulating levels of adiponectin and leptin have a reciprocal relationship (43). In the present studies, depot and diabetes-related differences in adiponectin secretion were not observed to occur with leptin secretion. In contrast to adiponectin, leptin secretion remained stable in culture regardless of depot source or diabetic status. Consistent with published reports (51), both ND and T2D SAT had a greater tendency for leptin secretion compared with VAT (Fig. 5), further supporting the validity of our experimental system.

One possible explanation for the reduction in adiponectin secretion is a parallel depletion of cellular adiponectin content. However, cellular adiponectin content did not decrease over time in culture. Therefore, observed reductions in media adiponectin suggest a change in the regulation of adiponectin secretion distal to protein synthesis.

TZDs are PPAR{gamma} agonists widely used for their insulin-sensitizing activity (38). In vivo (40, 50) and in vitro (40), TZDs enhance the expression of adiponectin mRNA and protein. Consistent with its in vivo effects on circulating adiponectin levels, we report in human AT direct effects of TZDs to significantly increase adiponectin secretion from cultured SAT explants obtained from both ND and T2D subjects. In contrast, VAT was resistant to TZD-mediated stimulation of adiponectin secretion, suggesting that depot differences may reflect not only the responsiveness of SAT but also the lack of the same in VAT. Intriguingly, in vivo TZD treatment is associated with an increase in SAT and a stabilization or possible reduction in VAT mass (33). Although the underlying molecular mechanism for this depot remodeling is not known, it may relate to an elevation in the expression of PPAR{gamma} and increased responsiveness to TZD agonism by SAT preadipocytes (52). These demonstrated direct effects of TZDs on AT are consistent with the prevailing view of AT as the primary target of TZD action. Our findings, together with those of Bodles et al. (4), differ from those of Motoshima et al. (45), who report that TZD augments adiponectin secretion from visceral but not subcutaneous adipocytes. The difference in results likely relates to a difference in experimental methods. Our use of explant culture, wherein isolated pieces of fat are placed in culture, has the advantage of ensuring that stromal or regulatory factors remain associated with adipocytes. In isolated cell culture this relationship of the adipocyte to the nonadipocyte components is lost, potentially impacting paracrine regulation of adiponectin secretion. With regard to SAT responsiveness, our findings are in agreement with the previous report (45), where no TZD-mediated increase in SAT adiponectin release was seen by 48 h (Figs. 3A and 4A).

Depot specificity was also observed in TZD responsiveness for cellular content. Of interest, ND VAT increased cellular adiponectin following pio treatment but in contrast to SAT, there was no parallel increase in adiponectin secretion. In T2D VAT there is a failure to both increase and secrete cellular adiponectin in response to TZDs. Several insights are suggested from these studies. First, only SAT, regardless of diabetic status, exhibits the capacity to respond to TZDs by increases in both cellular and secreted adiponectin. Second, given the dissociation between increases in cellular adiponectin and secretion observed in VAT, depot differences likely also exist in the regulation of adiponectin secretion.

Similar to another report (21), TZD treatment was associated with inhibition of leptin secretion by explants. These findings of increased adiponectin and decreased leptin following TZD treatment mirror not only the in vivo reciprocal regulation of these factors but further demonstrate depot-specific responsiveness and highlight that, in regard to TZD treatment, leptin secretion from VAT remains responsive.

Although descriptive, this study of AT in culture has revealed several properties of adiponectin secretion that are depot dependent. Adiponectin secretion over the first 48 h correlates with in vivo GDR and may be thought to be reflective of the in vivo environment; conversely, the behavior of AT over the remainder of the culture period reveals characteristics intrinsic to the tissue. Given the greater mass of the SAT depot and its now demonstrated greater capacity for adiponectin secretion, SAT likely exerts a greater influence on circulating adiponectin than VAT. In the presence of diabetes, this greater capacity for adiponectin secretion is lost and may contribute to the negative impact of diabetes on circulating adiponectin levels seen in vivo (3, 30, 62). The ability of Pio to directly stimulate adiponectin secretion in SAT suggests that this depot may also be responsible for adaptive responses of circulating adiponectin as observed in vivo (50). VAT manifests two defects with regard to regulation of adiponectin: an inability to sustain secretion and a selective nonresponsiveness to TZDs. This observation would amplify the benefit derived from AT remodeling noted after TZD treatment (15) i.e., selective loss of the nonresponsive depot (VAT) with gain in the more responsive (SAT) depot. The fact that Pio treatment can induce changes in cellular adiponectin in VAT while not altering adiponectin secretion indicates that adiponectin secretion is a regulated process.

There are several possible mechanistic explanations for our observations. Depot differences may exist both in the machinery responsible for the regulated release of adiponectin (61) and in the nonadipocyte components of AT (14, 57). For example, Wang et al. (61) reported that AT depots can differ in their expression of ERp44 and Ero1-L{alpha}, endoplasmic reticulum chaperone proteins that modulate the secretion of adiponectin, and that these chaperones are PPAR{gamma} targets (61). Regarding nonadipocyte constituents of AT, greater macrophage infiltration and inflammatory cytokine production reported in VAT compared with SAT could negatively impact adiponectin secretion and contribute to the observed depot differences (6), although the differences in cytokine secretion that we observed would not explain the decreases in adiponectin that we report.

A consideration regarding these studies is that observed changes in adiponectin and leptin might reflect effects of hypoxia on explants over the 7-day culture period (26, 60). Reports of the effects of hypoxia on AT are notable for increases in the expression and secretion of leptin, TNF-{alpha}, IL-6, macrophage migration inhibitory factor, PAI-1, anaerobic glycolysis, and, importantly, a decrease in expression of adiponectin and PPAR{gamma}2 and secretion of adiponectin. In our studies, we found an increase in adiponectin content throughout the culture period, and no elevations of IL-6, TNF-{alpha}, MCP-1, or vascular endothelial growth factor. A lack of change of media pH or lactate levels during culture suggests that anerobic glycolysis was stable, ruling out a potential influence of hypoxia.

The results suggest that that regional adipose tissue distribution, because of its impact on adiponectin responsivity, may be a predictor of the clinical response to insulin-sensitizing therapies. One limitation to these studies is that they reflect changes in total adiponectin and do not recognize the potential influence of depot differences and TZD-mediated changes in adiponectin multimerization. These important studies are in progress. Our data further support the hypothesis that there exist two mechanisms underlying the observed benefits of TZD treatment: depot remodeling and stimulation of adiponectin secretion. We further suggest that one possible cause for TZD treatment failure in a subset of T2D subjects could be a preponderance of VAT, as well as a failure to remodel.


   DISCLOSURES
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 DISCLOSURES
REFERENCES
 
Dr. Robert R. Henry is on the Speaker's Bureau and is a retained consultant for Takeda, the maker of pioglitazone.


   ACKNOWLEDGMENTS
 
This work was supported by National Institute of Diabetes and Digestive and Kidney Disease Grants KO8-DK-061987 (S. A. Phillips) and RO1-DK-258291 (R. R. Henry); a Distinguished Clinical Scientist Award from the American Diabetes Association (R. R. Henry); a VA Merit Review grant from the Medical Research Service, Department of Veterans Affairs and VA San Diego Healthcare System; and Grant M01-RR-00827 in support of the General Clinical Research Center from the General Clinical Research Branch, Division of Research Resources, NIH.


   FOOTNOTES
 

Address for reprint requests and other correspondence: S. A. Phillips, VA San Diego Healthcare System (9111G), 3350 La Jolla Village Dr., San Diego, CA 92161 (e-mail: saphillips{at}ucsd.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 DISCLOSURES
 REFERENCES
 

  1. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 46: 860–867, 1997.[Abstract]
  2. Appel B, Fried SK. Effects of insulin and dexamethasone on lipoprotein lipase in human adipose tissue. Am J Physiol Endocrinol Metab 262: E695–E699, 1992.[Abstract/Free Full Text]
  3. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257: 79–83, 1999.[CrossRef][Web of Science][Medline]
  4. Bodles AM, Banga A, Rasouli N, Ono F, Kern PA, Owens RJ. Pioglitazone increases secretion of high-molecular-weight adiponectin from adipocytes. Am J Physiol Endocrinol Metab 291: E1100–E1105, 2006.[Abstract/Free Full Text]
  5. Bolinder J, Kager L, Ostman J, Arner P. Differences at the receptor and postreceptor levels between human omental and subcutaneous adipose tissue in the action of insulin on lipolysis. Diabetes 32: 117–123, 1983.[Abstract]
  6. Bruun JM, Lihn AS, Pedersen SB, Richelsen B. Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): implication of macrophages resident in the AT. J Clin Endocrinol Metab 90: 2282–2289, 2005.[Abstract/Free Full Text]
  7. Christensen ML, Meibohm B, Capparelli EV, Velasquez-Mieyer P, Burghen GA, Tamborlane WV. Single- and multiple-dose pharmacokinetics of pioglitazone in adolescents with type 2 diabetes. J Clin Pharmacol 45: 1137–1144, 2005.[Abstract/Free Full Text]
  8. Ciaraldi TP, Kolterman OG, Olefsky JM. Mechanism of the postreceptor defect in insulin action in human obesity. Decrease in glucose transport system activity. J Clin Invest 68: 875–880, 1981.[Web of Science][Medline]
  9. Ciaraldi TP, Kolterman OG, Scarlett JA, Kao M, Olefsky JM. Role of glucose transport in the postreceptor defect of non-insulin-dependent diabetes mellitus. Diabetes 31: 1016–1022, 1982.[Web of Science][Medline]
  10. Ciaraldi TP, Maisel A. Role of guanine nucleotide regulatory proteins in insulin stimulation of glucose transport in rat adipocytes. Influence of bacterial toxins. Biochem J 264: 389–396, 1989.[Web of Science][Medline]
  11. Ciaraldi TP, Oh DK, Christiansen L, Nikoulina SE, Kong AP, Baxi S, Mudaliar S, Henry RR. Tissue-specific expression and regulation of GSK-3 in human skeletal muscle and adipose tissue. Am J Physiol Endocrinol Metab 291: E891–E898, 2006.[Abstract/Free Full Text]
  12. Cnop M, Landchild MJ, Vidal J, Havel PJ, Knowles NG, Carr DR, Wang F, Hull RL, Boyko EJ, Retzlaff BM, Walden CE, Knopp RH, Kahn SE. The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations: distinct metabolic effects of two fat compartments. Diabetes 51: 1005–1015, 2002.[Abstract/Free Full Text]
  13. Combs TP, Wagner JA, Berger J, Doebber T, Wang WJ, Zhang BB, Tanen M, Berg AH, O'Rahilly S, Savage DB, Chatterjee K, Weiss S, Larson PJ, Gottesdiener KM, Gertz BJ, Charron MJ, Scherer PE, Moller DE. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 143: 998–1007, 2002.[Abstract/Free Full Text]
  14. de Luca C, Olefsky JM. Inflammation and insulin resistance. FEBS Lett 582: 97–105, 2008.[CrossRef][Web of Science][Medline]
  15. de Souza CJ, Eckhardt M, Gagen K, Dong M, Chen W, Laurent D, Burkey BF. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 50: 1863–1871, 2001.[Abstract/Free Full Text]
  16. De Vos P, Lefebvre AM, Miller SG, Guerre-Millo M, Wong K, Saladin R, Hamann LG, Staels B, Briggs MR, Auwerx J. Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. J Clin Invest 98: 1004–1009, 1996.[Web of Science][Medline]
  17. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol Endocrinol Metab Gastrointest Physiol 237: E214–E223, 1979.[Abstract/Free Full Text]
  18. Degawa-Yamauchi M, Moss KA, Bovenkerk JE, Shankar SS, Morrison CL, Lelliott CJ, Vidal-Puig A, Jones R, Considine RV. Regulation of adiponectin expression in human adipocytes: effects of adiposity, glucocorticoids, and tumor necrosis factor alpha. Obes Res 13: 662–669, 2005.[Web of Science][Medline]
  19. Despres JP. Abdominal obesity as important component of insulin-resistance syndrome. Nutrition 9: 452–459, 1993.[Web of Science][Medline]
  20. Edens NK, Fried SK, Kral JG, Hirsch J, Leibel RL. In vitro lipid synthesis in human adipose tissue from three abdominal sites. Am J Physiol Endocrinol Metab 265: E374–E379, 1993.[Abstract/Free Full Text]
  21. Fain JN, Cowan GS Jr, Buffington C, Andersen RN, Pouncey L, Bahouth SW. Regulation of leptin release by troglitazone in human adipose tissue. Metabolism 49: 1485–1490, 2000.[CrossRef][Web of Science][Medline]
  22. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 145: 2273–2282, 2004.[Abstract/Free Full Text]
  23. Fisher FM, McTernan PG, Valsamakis G, Chetty R, Harte AL, Anwar AJ, Starcynski J, Crocker J, Barnett AH, McTernan CL, Kumar S. Differences in adiponectin protein expression: effect of fat depots and type 2 diabetic status. Horm Metab Res 34: 650–654, 2002.[CrossRef][Web of Science][Medline]
  24. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 83: 847–850, 1998.[Abstract/Free Full Text]
  25. Fried SK, Moustaid-Moussa N. Culture of adipose tissue and isolated adipocytes. Methods Mol Biol 155: 197–212, 2001.[Medline]
  26. Gesta S, Lolmede K, Daviaud D, Berlan M, Bouloumie A, Lafontan M, Valet P, Saulnier-Blache JS. Culture of human adipose tissue explants leads to profound alteration of adipocyte gene expression. Horm Metab Res 35: 158–163, 2003.[CrossRef][Web of Science][Medline]
  27. Hauner H. Secretory factors from human adipose tissue and their functional role. Proc Nutr Soc 64: 163–169, 2005.[CrossRef][Web of Science][Medline]
  28. Havel PJ. Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes 53, Suppl 1: S143–S151, 2004.[Abstract/Free Full Text]
  29. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20: 1595–1599, 2000.[Abstract/Free Full Text]
  30. Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC, Matsuzawa Y. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 50: 1126–1133, 2001.[Abstract/Free Full Text]
  31. Janand-Delenne B, Chagnaud C, Raccah D, Alessi MC, Juhan-Vague I, Vague P. Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women. Int J Obes Relat Metab Disord 22: 312–317, 1998.[CrossRef][Web of Science][Medline]
  32. Kannel WB, Cupples LA, Ramaswami R, Stokes J 3rd, Kreger BE, Higgins M. Regional obesity and risk of cardiovascular disease; the Framingham Study. J Clin Epidemiol 44: 183–190, 1991.[CrossRef][Web of Science][Medline]
  33. Kelly IE, Han TS, Walsh K, Lean ME. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 22: 288–293, 1999.[Abstract/Free Full Text]
  34. Krotkiewski M, Bjorntorp P, Sjostrom L, Smith U. Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. J Clin Invest 72: 1150–1162, 1983.[Web of Science][Medline]
  35. Larsson B. Obesity, fat distribution and cardiovascular disease. Int J Obes 15, Suppl 2: 53–57, 1991.[Medline]
  36. Laviola L, Perrini S, Cignarelli A, Natalicchio A, Leonardini A, De Stefano F, Cuscito M, De Fazio M, Memeo V, Neri V, Cignarelli M, Giorgino R, Giorgino F. Insulin signaling in human visceral and subcutaneous adipose tissue in vivo. Diabetes 55: 952–961, 2006.[Abstract/Free Full Text]
  37. Lefebvre AM, Laville M, Vega N, Riou JP, van Gaal L, Auwerx J, Vidal H. Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes 47: 98–103, 1998.[Abstract]
  38. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPARgamma). J Biol Chem 270: 12953–12956, 1995.[Abstract/Free Full Text]
  39. Lihn AS, Bruun JM, He G, Pedersen SB, Jensen PF, Richelsen B. Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol Cell Endocrinol 219: 9–15, 2004.[CrossRef][Web of Science][Medline]
  40. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50: 2094–2099, 2001.[Abstract/Free Full Text]
  41. Malavazos AE, Cereda E, Morricone L, Coman C, Corsi MM, Ambrosi B. Monocyte chemoattractant protein 1: a possible link between visceral adipose tissue-associated inflammation and subclinical echocardiographic abnormalities in uncomplicated obesity. Eur J Endocrinol Eur Fed Endocr Soc 153: 871–877, 2005.
  42. Malavazos AE, Corsi MM, Ermetici F, Coman C, Sardanelli F, Rossi A, Morricone L, Ambrosi B. Proinflammatory cytokines and cardiac abnormalities in uncomplicated obesity: relationship with abdominal fat deposition. Nutr Metab Cardiovasc Dis 17: 294–302, 2007.[CrossRef][Web of Science][Medline]
  43. Matsubara M, Maruoka S, Katayose S. Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur J Endocrinol Eur Fed Endocr Soc 147: 173–180, 2002.
  44. Montague CT, Prins JB, Sanders L, Zhang J, Sewter CP, Digby J, Byrne CD, O'Rahilly S. Depot-related gene expression in human subcutaneous and omental adipocytes. Diabetes 47: 1384–1391, 1998.[Abstract/Free Full Text]
  45. Motoshima H, Wu X, Sinha MK, Hardy VE, Rosato EL, Barbot DJ, Rosato FE, Goldstein BJ. Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J Clin Endocrinol Metab 87: 5662–5667, 2002.[Abstract/Free Full Text]
  46. Nannipieri M, Bonotti A, Anselmino M, Cecchetti F, Madec S, Mancini E, Baldi S, Santini F, Pinchera A, Rossi M, Ferrannini E. Pattern of expression of adiponectin receptors in human adipose tissue depots and its relation to the metabolic state. Int J Obes (Lond) 31: 1843–1848, 2007.[CrossRef][Medline]
  47. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, Ishigami M, Kuriyama H, Kishida K, Nishizawa H, Hotta K, Muraguchi M, Ohmoto Y, Yamashita S, Funahashi T, Matsuzawa Y. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103: 1057–1063, 2001.[Abstract/Free Full Text]
  48. Patel DA, Srinivasan SR, Xu JH, Chen W, Berenson GS. Adiponectin and its correlates of cardiovascular risk in young adults: the Bogalusa Heart Study. Metabolism 55: 1551–1557, 2006.[CrossRef][Web of Science][Medline]
  49. Perrini S, Laviola L, Cignarelli A, Melchiorre M, De Stefano F, Caccioppoli C, Natalicchio A, Orlando MR, Garruti G, De Fazio M, Catalano G, Memeo V, Giorgino R, Giorgino F. Fat depot-related differences in gene expression, adiponectin secretion, and insulin action and signalling in human adipocytes differentiated in vitro from precursor stromal cells. Diabetologia 51: 155–164, 2008.[CrossRef][Web of Science][Medline]
  50. Phillips SA, Ciaraldi TP, Kong AP, Bandukwala R, Aroda V, Carter L, Baxi S, Mudaliar SR, Henry RR. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes 52: 667–674, 2003.[Abstract/Free Full Text]
  51. Russell CD, Petersen RN, Rao SP, Ricci MR, Prasad A, Zhang Y, Brolin RE, Fried SK. Leptin expression in adipose tissue from obese humans: depot-specific regulation by insulin and dexamethasone. Am J Physiol Endocrinol Metab 275: E507–E515, 1998.[Abstract/Free Full Text]
  52. Sewter CP, Blows F, Vidal-Puig A, O'Rahilly S. Regional differences in the response of human pre-adipocytes to PPARgamma and RXRalpha agonists. Diabetes 51: 718–723, 2002.[Abstract/Free Full Text]
  53. Statnick MA, Beavers LS, Conner LJ, Corominola H, Johnson D, Hammond CD, Rafaeloff-Phail R, Seng T, Suter TM, Sluka JP, Ravussin E, Gadski RA, Caro JF. Decreased expression of apM1 in omental and subcutaneous adipose tissue of humans with type 2 diabetes. Int J Exper Diabetes Res 1: 81–88, 2000.[CrossRef]
  54. Thies RS, Molina JM, Ciaraldi TP, Freidenberg GR, Olefsky JM. Insulin-receptor autophosphorylation and endogenous substrate phosphorylation in human adipocytes from control, obese, and NIDDM subjects. Diabetes 39: 250–259, 1990.[Abstract]
  55. Trujillo ME, Scherer PE. Adipose tissue-derived factors: impact on health and disease. Endocr Rev 27: 762–778, 2006.[Abstract/Free Full Text]
  56. Van Harmelen V, Reynisdottir S, Eriksson P, Thorne A, Hoffstedt J, Lonnqvist F, Arner P. Leptin secretion from subcutaneous and visceral adipose tissue in women. Diabetes 47: 913–917, 1998.[Abstract]
  57. Villena JA, Cousin B, Penicaud L, Casteilla L. Adipose tissues display differential phagocytic and microbicidal activities depending on their localization. Int J Obes Relat Metab Disord 25: 1275–1280, 2001.[CrossRef][Web of Science][Medline]
  58. Wabitsch M, Jensen PB, Blum WF, Christoffersen CT, Englaro P, Heinze E, Rascher W, Teller W, Tornqvist H, Hauner H. Insulin and cortisol promote leptin production in cultured human fat cells. Diabetes 45: 1435–1438, 1996.[Abstract]
  59. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 21: 697–738, 2000.[Abstract/Free Full Text]
  60. Wang B, Wood IS, Trayhurn P. Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes. Pflügers Arch 455: 479–492, 2007.[CrossRef][Web of Science][Medline]
  61. Wang Y, Lam KS, Yau MH, Xu A. Post-translational modifications of adiponectin: mechanisms and functional implications. Biochem J 409: 623–633, 2008.[CrossRef][Web of Science][Medline]
  62. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86: 1930–1935, 2001.[Abstract/Free Full Text]
  63. Yang WS, Chen MH, Lee WJ, Lee KC, Chao CL, Huang KC, Chen CL, Tai TY, Chuang LM. Adiponectin mRNA levels in the abdominal adipose depots of nondiabetic women. Int J Obes Relat Metab Disord 27: 896–900, 2003.[CrossRef][Web of Science][Medline]
  64. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama Y, Matsuzawa Y. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96: 1723–1732, 2000.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
Y. Liu, S. Chewchuk, C. Lavigne, S. Brule, G. Pilon, V. Houde, A. Xu, A. Marette, and G. Sweeney
Functional significance of skeletal muscle adiponectin production, changes in animal models of obesity and diabetes, and regulation by rosiglitazone treatment
Am J Physiol Endocrinol Metab, September 1, 2009; 297(3): E657 - E664.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
M. J. Laye, R. S. Rector, S. O. Warner, S. P. Naples, A. L. Perretta, G. M. Uptergrove, M. H. Laughlin, J. P. Thyfault, F. W. Booth, and J. A. Ibdah
Changes in visceral adipose tissue mitochondrial content with type 2 diabetes and daily voluntary wheel running in OLETF rats
J. Physiol., July 15, 2009; 587(14): 3729 - 3739.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
Z. Kovacova, M. Vitkova, M. Kovacikova, E. Klimcakova, M. Bajzova, Z. Hnevkovska, L. Rossmeislova, V. Stich, D. Langin, and J. Polak
Secretion of adiponectin multimeric complexes from adipose tissue explants is not modified by very low calorie diet
Eur. J. Endocrinol., April 1, 2009; 160(4): 585 - 592.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
295/4/E842    most recent
90359.2008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Phillips, S. A.
Right arrow Articles by Henry, R. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Phillips, S. A.
Right arrow Articles by Henry, R. R.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.